A Bayesian hierarchical surrogate outcome model for multiple sclerosis-Reference-Cited by-同舟云学术

A Bayesian hierarchical surrogate outcome model for multiple sclerosis

Published:2016-04-07 Issue:4 Volume:15 Page:341-348
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceut. Statist.

Author:

Pozzi Luca¹,Schmidli Heinz²,Ohlssen David I.³

Affiliation:

1. Division of Biostatistics; University of California Berkeley; Berkeley 94720-7358 CA USA

2. Statistical Methodology, Development; Novartis Pharma AG; Basel Switzerland

3. Statistical Methodology, Development; Novartis Pharmaceuticals Corporation; East Hanover 07936-1080 NJ USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Reference37 articles.

1. Are surrogate markers adequate to assess cardiovascular disease drugs?;Temple;JAMA: The Journal of the American Medical Association,1999

2. Statistical evaluation of biomarkers as surrogate endpoints: a literature review;Weir;Statistics in Medicine,2006

3. Surrogate endpoints for EDSS worsening in multiple sclerosis;Sormani;Neurology,2010

4. Qin L Magnetic resonance imaging lesion count as a surrogate endpoint in relapsing-remitting multiple sclerosis clinical trials Master's Thesis 2011

5. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis;Sormani;Neurology,2011

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An analytical review on the use of artificial intelligence and machine learning in diagnosis, prediction, and risk factor analysis of multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-09

2. Utilization of treatment effect on a surrogate endpoint for planning a study to evaluate treatment effect on a final endpoint;Pharmaceutical Statistics;2023-03-03

3. Development of Bayesian Network for Multiple Sclerosis Risk Factor Interaction Analysis;Computational Intelligence Methods for Bioinformatics and Biostatistics;2022

4. Adaptive Clinical Trial Designs with Surrogates: When Should We Bother?;Management Science;2021-12-22

5. Current review and next steps for artificial intelligence in multiple sclerosis risk research;Computers in Biology and Medicine;2021-05